NASDAQ:PRTO

Proteon Therapeutics Stock Insider Trading

> Biotechnology

Buy PRTO

*Your capital is at risk

$27.88

-0.0562 (-0.201%)

At Close: Jun 03, 2026

Proteon Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 26.7M and sold 73.04M PRTO shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	0
● Buy	26.7M shares
● Sell	73.04M shares
71% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 07, 2015 Buy	Stock Option (Right to Buy) A-Award	Gottlieb Daniel Philip Vp Marketing & Business Dev't	Officer	26 699 Value: $283.3K
Oct 27, 2014 Buy	Common Stock X-InTheMoney	Birner Hubert	Director	39 932 Value: $183.8K
Oct 27, 2014 Buy	Common Stock X-InTheMoney	Birner Hubert	Director	116 511 Value: $536.2K
Oct 27, 2014 Buy	Common Stock C-Conversion	Birner Hubert	Director	379 462 Value: $0
Oct 27, 2014 Buy	Common Stock C-Conversion	Birner Hubert	Director	1 107 154 Value: $0
Oct 27, 2014 Buy	Common Stock P-Purchase	Birner Hubert	Director	76 590 Value: $765.9K
Oct 27, 2014 Buy	Common Stock P-Purchase	Birner Hubert	Director	223 410 Value: $2.23M
Oct 27, 2014 Sell	Series C Convertible Preferred Stock C-Conversion	Birner Hubert	Director	799 043 Value: $0
Oct 27, 2014 Sell	Option (Right to Purchase) J-Other	Birner Hubert	Director	451 276 Value: $0
Oct 27, 2014 Sell	Series A Convertible Preferred Stock C-Conversion	Birner Hubert	Director	1 531 518 Value: $0
Oct 27, 2014 Sell	Series A-1 Convertible Preferred Stock C-Conversion	Birner Hubert	Director	717 260 Value: $0
Oct 27, 2014 Sell	Series B Convertible Preferred Stock C-Conversion	Birner Hubert	Director	835 121 Value: $0
Oct 27, 2014 Sell	Series D Convertible Preferred Stock C-Conversion	Birner Hubert	Director	1 277 663 Value: $0
Oct 27, 2014 Sell	Warrants (Right to Buy) X-InTheMoney	Birner Hubert	Director	39 932 Value: $183.8K
Oct 27, 2014 Buy	Common Stock X-InTheMoney	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	39 932 Value: $183.8K
Oct 27, 2014 Buy	Common Stock X-InTheMoney	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	116 511 Value: $536.2K
Oct 27, 2014 Buy	Common Stock C-Conversion	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	379 462 Value: $0
Oct 27, 2014 Buy	Common Stock C-Conversion	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	1 107 154 Value: $0
Oct 27, 2014 Buy	Common Stock P-Purchase	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	76 590 Value: $765.9K
Oct 27, 2014 Buy	Common Stock P-Purchase	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	223 410 Value: $2.23M
Oct 27, 2014 Sell	Option (Right to Purchase) J-Other	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	451 276 Value: $0
Oct 27, 2014 Sell	Series A Convertible Preferred Stock C-Conversion	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	1 531 518 Value: $0
Oct 27, 2014 Sell	Warrants (Right to Buy) X-InTheMoney	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	39 932 Value: $183.8K
Oct 27, 2014 Sell	Series C Convertible Preferred Stock C-Conversion	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	799 043 Value: $0
Oct 27, 2014 Sell	Series A-1 Convertible Preferred Stock C-Conversion	Tvm Life Science Ventures Vi Gmbh & Co Kg 10 Percent Owner	10% Owner	717 260 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTEON THERAPEUTICS INC.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials ...

Read Full Profile Here